WO2023198640A1 - Modified release pharmaceutical formulations comprising deferiprone - Google Patents
Modified release pharmaceutical formulations comprising deferiprone Download PDFInfo
- Publication number
- WO2023198640A1 WO2023198640A1 PCT/EP2023/059303 EP2023059303W WO2023198640A1 WO 2023198640 A1 WO2023198640 A1 WO 2023198640A1 EP 2023059303 W EP2023059303 W EP 2023059303W WO 2023198640 A1 WO2023198640 A1 WO 2023198640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical formulation
- tablet
- formulation according
- deferiprone
- mixture
- Prior art date
Links
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229960003266 deferiprone Drugs 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 239000003826 tablet Substances 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims description 56
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 30
- 229920000642 polymer Polymers 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 22
- 238000000576 coating method Methods 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 20
- 239000002702 enteric coating Substances 0.000 claims description 19
- 238000009505 enteric coating Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229910052742 iron Inorganic materials 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 206010065973 Iron Overload Diseases 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000006185 dispersion Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000002662 enteric coated tablet Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 208000007056 sickle cell anemia Diseases 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 235000012222 talc Nutrition 0.000 claims description 5
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 abstract description 3
- 239000007950 delayed release tablet Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 17
- 229920003091 Methocel™ Polymers 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000007922 dissolution test Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000013065 commercial product Substances 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940025452 ferriprox Drugs 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 5
- 239000007836 KH2PO4 Substances 0.000 description 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 3
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical group CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000035502 ADME Effects 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical class [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- -1 e.g. Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the invention relates to pharmaceutical formulations comprising the iron chelator deferiprone.
- the invention is directed to a modified release formulation suitable for twice-a- day oral administration for the treatment of iron overload which occurs in patients suffering for example, from thalassemia, sickle cell disease, hemochromatosis, and myelodysplasia.
- Deferiprone also known as 3-hydroxy- l,2-dimethylpyridin-4-one, is a bidentate ligand which binds to iron in a 3 : 1 molar ratio.
- iron overload is used in the treatment of generalized iron overload, particularly in conditions where frequent blood transfusions lead to iron overload including, e.g., thalassemia and Sickle Cell Disease (SCD).
- SCD Sickle Cell Disease
- LIC Liver Iron Concentration
- gastrointestinal disorders due to gastrointestinal irritation. Such discomfort could cause patients to refrain from taking the medication, leading to a worsening of their condition.
- Other observed adverse events are musculoskeletal disorders (arthralgia), Alanine Aminotransferase (ALT) increase, agranulocytosis and neutropenia.
- Agranulocytosis seems to be an idiosyncratic response and it is more frequent in the first year of treatment.
- the incidence of neutropenia and agranulocytosis is stable and seems to be not related with dose (Hider RC et al N Engl J Med. 2018;379:2140-2150).
- Deferiprone is endowed with a long half-life of 2-3 hour) but with an unpleasant bitter taste.
- Said drug is sold as Immediate Release (IR) 500 mg and 1000 mg tablets, as well as a 100 mg/ml liquid formulation, generally, under the trade name Ferriprox®.
- deferiprone In view of its pharmacological and ADME profile, and in order to improve the compliances of the patients, recently, deferiprone has also been launched commercially as 1000 mg Delayed Release (DR) tablets for oral administration. Said tablets are suitable for a twice daily administration being bioequivalent in the steady state to the same daily dose of an immediate release tablet administered three times daily.
- DR Delayed Release
- the commercial tablets are also debossed with a score line, to make it easy for the patient to break the tablets into two approximately equal parts for dosing flexibility.
- composition of the DR tablets has been disclosed in WO 2019/082128, and it comprises: (a) a core comprising the active pharmaceutical ingredient and an enteric polymer with pH- dependent solubility, and (b) an enteric coating.
- the oral pharmaceutical dosage forms containing deferiprone due to its potential for irritation and damage to the gastric mucosa and the relatively high solubility in an acid environment, shall be provided with an enteric coating (e.g. polymeric films with solubility at pH> 5 ) in order to avoid, or at least reduce, the release of the active principle during the permanence of the unit in the stomach, avoiding reaching plasma concentrations responsible for possible systemic adverse reactions.
- an enteric coating e.g. polymeric films with solubility at pH> 5
- HPMC-AS hydroxypropyl methylcellulose acetate succinate
- HPMC-AS has a pH-dependent solubility.
- the invention provides a pharmaceutical formulation in form of modified release enteric coated tablets suitable for twice-a-day oral administration, wherein the core of the tablet comprises: a) deferiprone in an amount comprised between 85.0 to 95.0%, b) a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP as a modifying release agent in an amount comprised between 4.0 and 10.0%, c) a lubricant and/or glidant in an amount from 0.2 to 2.0%, and d) other suitable pharmaceutically acceptable excipients in an amount comprised between from 0 to 5%, all the amounts calculated by weight on the total weight of the formulation.
- Suitable pharmaceutically acceptable excipients may belong to the classes of pH adjusting agents, and bulking agents.
- the invention provides a process for the preparation of a coated deferiprone tablet as described above, which process comprises the following steps:
- step (ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce a granulate;
- step (iii) mixing the granulate obtained in step (ii) with the lubricant and/or glidant excipient to form a mixture;
- step (iv) compressing the mixture obtained in step (iii) to form a tablet
- the process comprises the steps of:
- step (iii) directly compressing the mixture obtained in step (ii) to form a tablet
- the invention is directed to the claimed pharmaceutical composition for use for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron.
- the invention is directed to the claimed pharmaceutical composition in the manufacture of a medicament for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron.
- the invention refers to a method for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron thereof in a patient in a need thereof, said method comprising orally administering the claimed pharmaceutical composition.
- Figure 1 Dissolution tests of HPMC formulations carried out in 900 ml of pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm.
- the line with a triangular indicator is referred to as the commercial product.
- Figure 2- Dissolution tests of HPMC formulations carried out in 900 ml of pH 4.5 medium, paddle (apparatus 2) having rotational speed of 50 rpm.
- the line with a triangular indicator is referred to as the commercial product.
- Figure 4 Dissolution tests of HPMC formulations carried out in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm.
- the line with a triangular indicator is referred to as the commercial product
- FIG. 5 Dissolution tests of HPMC formulations carried out in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm.
- the line with a triangular indicator is referred to as the commercial product
- Figure 6 Dissolution tests of the half-coated tablets in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm.
- the line with a triangular indicator is referred to as the commercial product
- a tablet refers to one or more tablets.
- active ingredient or “active pharmaceutical ingredient” (API) or “drug” are used as synonymous and mean any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals.
- iron overload or "overload of iron” are used interchangeably herein and refer to medical conditions where the body contains or stores too much (or “excess”) iron.
- An example is transfusional iron overload, where the excess iron is introduced by one or more blood transfusions.
- hydrophilic describes that something 'likes water', i.e. a hydrophilic molecule or portion of a molecule is one that typically is electrically polarized and capable of forming hydrogen bonds with water molecules, enabling it dissolve more readily in water than in oil or other "non-polar" solvents.
- hydrophobic denotes a compound tending to be electrically neutral and non-polar, and thus preferring other neutral and nonpolar solvents or molecular environments.
- pH dependent solubility it is meant a substance having different solubilities at different pHs. These pH-dependent solubility differences lead to pH-dependent dissolution profiles.
- insoluble or poorly water soluble refers to a substance having a solubility in water as defined in the European Pharmacopoeia Ed. 4 th , 2003, page 2891.
- Core or “tablet core” as used herein comprises an active ingredient, e.g., deferiprone, and one or more excipients compressed into an uncoated tablet.
- the core can be coated with various coatings, including an enteric coating.
- controlled release In the present context, the terms "controlled release”, “prolonged release”, “modified release” and “delayed release” are intended to be equivalent terms covering any type of release of deferiprone from a composition of the invention that is appropriate to obtain a specific therapeutic or prophylactic response after administration to a subject".
- the terms refer to protecting an active ingredient, e.g., deferiprone, from rapid release at acidic pH, e.g., in the stomach, while enabling the active ingredient to be released at a higher rate at a higher pH, e.g., in the intestines.
- DR will be understood to mean that, when tested in USP apparatus 2 at 75 rpm, the extent of dissolution will be around 20 ⁇ 5% at 1 hour in 0.1N HC1, and the rate of dissolution will be substantially higher (e.g., over 30%, e.g. over 40%, in 1 hour) in phosphate buffer with pH 6.8 than the rate of dissolution in 0. IN HC1.
- Disintegrant refers to an excipient that is insoluble in water, but swells when wetted to cause a tablet to disintegrate.
- disintegrate refers to the process by which a solute forms a solution in a solvent.
- Enteric coat or "enteric coating” as used herein refers to a coating comprising an enteric polymer.
- An enteric coating can serve to prevent or delay a tablet's dissolution or disintegration in a gastric environment.
- burst effect it is meant the initial rapid release before the release rate reaches a stable profile, occurring immediately upon at the change of pH in the release medium.
- Enteric coated tablet means a tablet having a core comprising an active ingredient, which is coated with an enteric coating.
- Enteric polymer as used herein is understood to mean a polymer that is relatively insoluble at the acidic pH of the fasted stomach (e.g., about pH 1 to about pH 4), but soluble at higher pH (e.g., about pH 4.5 to about pH 8), which corresponds to the pH in the small intestine or thereafter, particularly in the duodenum or ileum.
- bioequivalence it is meant the absence of a significant difference between the bioavailability, i.e., the extent of absorption and peak concentration, between two pharmaceutical drug products (e.g., a test product and a reference product) over the course of a period of time, at the same dose and under the same conditions,
- test product is bioequivalent to a reference product
- a bioequivalence or comparative bioavailability study is determined by performing a study, referred to as a bioequivalence or comparative bioavailability study, in a group of subjects, usually about 18-36 subjects or more, under controlled conditions.
- the study can be done in a "crossover" design, which means that the study is done in 2 or more phases, usually at least a week apart, depending in part on the half-life of the drug.
- first phase half the subjects are randomly assigned to ingest the test product first and the other half ingest the reference product first.
- each subject ingests the alternate product.
- blood samples are drawn from each subject, on a predetermined schedule after ingestion of the test product.
- the blood samples are then analyzed to determine serum concentrations of the drug (test product, e.g., deferiprone) at each time point.
- drugs are bioequivalent if they enter circulation at the same rate when given in similar doses under similar conditions.
- Parameters often used in bioequivalence studies are tmax, Cmax, Cmin, AUCo- inf ini ty , AUC 0-t .
- tmax denotes the time to reach the maximal plasma concentration (Cmax) after administration
- AUCo-infmity denotes the area under the plasma concentration versus time curve from time 0 to infinity
- AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t
- W50 denotes the time where the plasma concentration is 50% or more of Cma X
- W75 denotes the time where the plasma concentration is 75% or more of Cma X
- MRT denotes mean residence time for tacrolimus.
- “Fasted state” as used herein refers to abstinence from food for a defined period of time after a meal (typically, at least several hours, e.g., 4 or 6 hours, after a meal).
- “Fed state” as used herein refers to administration with a meal or soon after a meal (e.g., within about 1 hour).
- chemical stable refers to stability of the active agent in the formulation, wherein changes in the drug assay values and/or impurities content are equal to or lesser than 5%, preferably lesser than 3%, during storage at 25°C and 60% relative humidity (RH), or 40°C and 75% RH, for at least 1 month.
- IVIVC vitro-in vivo correlation
- Gastric distress refers to discomfort of the gastrointestinal (GI) tract, e.g., one or more of pain, cramping, bloating, nausea, indigestion, heartburn, and gas.
- Half tablet as used herein means either of the two parts of a tablet obtained by splitting the tablet into two parts of equal or approximately equal weight.
- a half tablet is from about 40% to about 60% by weight of the whole tablet from which the half was derived.
- the approximately equal weight of each half tablet is about 45-55% of the total weight of the whole tablet.
- Percent or “%” as used herein refers to weight percentage (w/w) unless otherwise specified.
- Scored tablet refers to a tablet that is debossed with one or more lines, also known as a “score line”, to facilitate splitting the tablet, e.g., to enable administration of a half tablet.
- the tablet can be scored with two, three, four, or more score lines.
- Tablet refers a solid oral pharmaceutical dosage form.
- the tablet is a compressed tablet.
- “Whole tablet” means a complete tablet, i.e., not broken or split into parts.
- the analogous unit in the International System of Units is the pascal-second (Pa-s). 1 cP corresponds to 1 mPa s.
- Terms such as “treating” or “treatment” or “to treat” or “ameliorating” or “alleviating” or “to alleviate” can refer to both 1) therapeutic measures that cure, slow down, lessen symptoms of, reverse, and/or halt progression of a diagnosed pathologic condition or disorder and 2) prophylactic or preventative measures that prevent, reduce the incidence of, reduce the risk of, and/or slow the development of a targeted pathologic condition or disorder.
- those in need of treatment include those who already have the disorder; those prone to developing the disorder; and those in whom the disorder is to be prevented.
- Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
- Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
- Those in need of treatment include those who already have the condition or disorder as well as those prone to developing the condition or disorder or those in which the condition or disorder is to be prevented or incidence reduced.
- subject or “individual” or “patient,” is meant any human subject, for whom diagnosis, prognosis, treatment, or therapy is desired.
- terapéuticaally effective dose or amount or “effective amount” is intended an amount of active pharmaceutical ingredient, e.g., deferiprone, that when administered brings about a positive therapeutic response with respect to treatment of or reducing the risk of a disease in a subject to be treated.
- the deferiprone DR tablets used as the "reference” or “reference product” herein are Ferriprox® tablets (1000 mg) as approved by FDA and sold in the United States.
- the present invention concerns pharmaceutical formulations for the prevention and/or treatment of diseases which are caused by an excess of iron, especially compositions providing modified release of the active ingredient.
- the active ingredient in the inventive formulations is deferiprone.
- deferiprone in any physical form (crystals, amorphous powder, any possible polymorphs, any possible solvate. Included are also pharmaceutically acceptable salts and/or solvates thereof.
- deferiprone is used as a base in its anhydrous form.
- the invention is directed to a pharmaceutical formulation in form of modified release enteric coated tablets suitable for twice-a-day oral administration, wherein the core of the tablet comprises; a) deferiprone in an amount comprised between 85.0 to 95.0%, b) a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP as a modifying release agent in an amount comprised between 4.0 and 10.0%, c) a lubricant and/or glidant in an amount from 0.2 to 2.0% and d) other suitable pharmaceutically acceptable excipients in an amount comprised between from 0 to 5%, all the amounts calculated by weight on the total weight of the formulation.
- the tablet-core of the pharmaceutical dosage form object of the present invention has the advantage of having a composition based on excipients with non-pH-dependent solubility, and hence they are not directly interfering with the release of deferiprone at the different pH values of the gastrointestinal tract.
- HPMC hydroxyproylmethylcellulose polymer
- Methocel® K100LV which is a thickener with low substitution, yielding a viscosity of about 100 cP at a 2% addition in water at 20°C.
- Said polymer could be used in combination with hydroxyproylmethylcellulose polymer (HPMC) Methocel®K4M which is a medium molecular weight hydroxypropyl methylcellulose (HPMC) thickener. It will yield a viscosity of about 4,000 cP at a 2% addition in water at 20°C.
- HPMC hydroxyproylmethylcellulose polymer
- Methocel®K4M which is a medium molecular weight hydroxypropyl methylcellulose (HPMC) thickener. It will yield a viscosity of about 4,000 cP at a 2% addition in water at 20°C.
- modifying release agent in present in an amount comprised between 4.0 and 10.0%, preferably between 7 and 8% by weight.
- Methocel® K100LV could be used alone in an amount of 7.5%, while in another preferred embodiment, a mixture of Methocel® K100LV and Methocel® K4M in an amount of 5% by weight could be utilised, preferably wherein the two polymers are in the amount of 2% and 3.0% by weight, respectively (ratio 40:60 w/w).
- Deferiprone may cause gastric irritation if released in the fasted stomach, and some degradation by acidic hydrolysis.
- the tablets of the invention will be provided by an enteric coating, which serves both to delay dissolution of deferiprone and to avoid dissolution in the stomach, in particular in fasted patient, and a diluent such as water, ethanol, propylene glycol or mixture thereof.
- a diluent such as water, ethanol, propylene glycol or mixture thereof.
- Suitable enteric polymers for the enteric coating include, e.g., hydroxyxypropyl methylcellulose acetate succinate (also referred to as hypromellose acetate succinate or HPMCAS), HPMC phthalate (also referred to as hypromellose phthalate), polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, shellac, zein, methacrylic acid copolymers (e.g., methacrylic acid copolymer Type C Dispersion 30%), derivatives thereof, and any combination thereof.
- HPMCAS hypromellose acetate succinate
- HPMC phthalate also referred to as hypromellose phthalate
- polyvinyl acetate phthalate polyvinyl acetate phthalate
- cellulose acetate phthalate cellulose acetate trimellitate
- shellac zein
- methacrylic acid copolymers e.g., meth
- the preferred enteric polymers in the enteric coating are HPMC acetate succinate and methacrylic acid copolymers, e.g., methacrylic acid copolymer type C, in aqueous dispersion.
- the enteric polymer in the coating is about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.5%, 3%, 3.5%, or 4%, by weight of the tablet, or a range between any two of the preceding values, e.g., 0.5-1%, 0.5-2%, 0.5-3%, 0.5-4%, 0.6-1%, 0.6-2%, 0.6-3%, 0.6-4%, 0.7-1%, 0.7-2%, 0.7-3%, 0.7-4%, 1-1.5%, 1.1- 1.7%, 1-2%, 1.5-2%, 1-3%, 1-3.5%, or 1-4%, by weight of the tablet.
- the enteric polymer in the coating is about 2.0% or about 3.0% by weight of the tablet.
- the enteric coating comprises, in addition to the enteric polymer, other excipients, including for example, a plasticizer, a lubricant or anti-tack agent such as talc, an opacifier, a colorant, a diluent, or any combination thereof.
- the enteric coating plasticizer is diethyl phthalate, citrate esters such as triethyl citrate, polyethylene glycol, glycerol, acetylated glycerides, acetylated citrate esters, dibutyl sebecate, castor oil, or any combination thereof.
- citrate esters such as triethyl citrate, polyethylene glycol, glycerol, acetylated glycerides, acetylated citrate esters, dibutyl sebecate, castor oil, or any combination thereof.
- the enteric coating may further comprise a diluent e.g., lactose, sucrose, fructose, mannitol, and the like, or combinations thereof.
- the enteric coating comprises talc as the lubricant or anti-tack agent.
- the enteric coating comprises a methacrylic acid copolymer dispersion, preferably an ethacrylic acid - ethyl acrylate copolymer (1 :1) dispersion in water and propylene glycol.
- the ethacrylic acid - ethyl acrylate copolymer (1 : 1) is known as Eudragit® L30- D55 and is commercially available from Evonik Operations GmbH, Essen Germany.
- the enteric coating comprises methacrylic acid- methacrylate copolymer (1 : 1) in an alcoholic solution, preferably in concentration of 5-15% w/w, more preferably 10% w/w, with tri ethyl citrate as plasticizer, preferably in a concentration in relation to the polymer of 2-5% w/w, more preferably of 3% w/w.
- Methacrylic acid- methacrylate copolymer (1 :1) is known as Eudragit® L100 (dissolution pH around 6.8) and is commercially available, for example from Sigma-Aldrich (Missouri, USA).
- the coating shall be performed according to methods known to the skilled person, typically for a time comprised 15 and 20 minutes.
- the core may comprise one or more pharmaceutically acceptable excipients such as bulking agents and/or basic excipient.
- the buking agent that when present is utilizes to increase tablet hardness could be selected from the group consisting of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrans, dextrin, dextrose, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, alpha-lactose monohydrate.
- the basic excipient could be selected from the group consisting of metal oxides, metal hydroxides, basic salts of weak acids, and a combination thereof.
- Metal oxides include, but are not limited to, magnesium oxide, aluminum oxide, and zinc oxide.
- Metal hydroxides include, but are not limited to, sodium hydroxide, potassium hydroxide, magnesium hydroxide, and calcium hydroxide.
- Basic salts of weak acids include, but are not limited to, sodium or potassium salts of carbonate, bicarbonate, acetate, and citrate.
- the basic excipient is magnesium oxide, meglumine or a combination thereof. In some embodiments, the basic excipient is magnesium oxide.
- the tablets shall also comprise a lubricant to prevent sticking to the tooling during compression into tablets), and/or a glidant to improve flow in the tableting process), or combinations thereof.
- the lubricant is selected from the group consisting of, but not limited to, magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, or combination thereof.
- the lubricant is magnesium stearate.
- the glidant is selected from the group consisting of, but not limited to, colloidal silicon dioxide, starch and talc, preferably colloidal silicon dioxide or any combination thereof.
- the core of tablet comprises a mixture of magnesium stearate and colloidal silicon dioxide.
- the core of said coated formulations comprises: a) deferiprone in an amount of 91% by weight; b) Methocel® K100LV in an amount of 7.5% by weight; and c) a mixture of a lubricant and glidant in an amount of 1.5% by weight.
- the core of the coated formulation comprises: a) deferiprone in an amount of 93% by weight: b) Methocel® K100LV in an amount of 2.0% by weight; c) Methocel ®K4M in an amount of 3.0 by weight; d) a mixture of a lubricant and glidant in an amount of 2.0% by weight.
- the pharmaceutical tablets of the invention are debossed with a score line, to make it easy for the patient to break the tablets into two approximately equal parts to enable administration of half tablets, allowing a dosing flexibility.
- the half tablets of the invention when a change of the pH occurs, do not show any undesired burst effect, and exhibit a smoother release of the active ingredient in the first phase of the dissolution.
- a tablet of the present disclosure embraces the attributes of an enteric coated tablet without its deficiencies, so that tablets can be halved, to enable fine tuning of the dosing to administer whole tablets, half tablets or any combination thereof.
- Half tablets of the disclosure substantially resist dissolution in acidic media (0.1 N HC1), representing the fasted stomach contents, as do whole tablets; and, at a higher pH, representing the contents of the small intestine, also exhibit a rate of dissolution similar to whole tablets, but without the undesired burst effect of the reference product on the market.
- the release profile of the tablets of the invention has been determined in different dissolution media varying the pH according to the conditions reported in Examples 2 and 3.
- the tablets according to the invention give rise to a dissolution profile at pH 6.8 similar to that of Ferriprox® tablets as approved by FDA and sold in the United States, so it is contemplated that they will show the same bioavailability at the steady state, making it suitable for a twice a day oral administration.
- said formulation would turn out to be bioequivalent in the steady state, to the immediate release Ferriprox® tablets for three times a day administration, the mean ratio of AUC (over 24 hours) and the mean ratio of Cmax for the tablets of the invention relative to the immediate release (IR) tablets would be within 80% to 125%.
- the modified release tablets of the present invention when administered twice-a-day would be able to achieve the same maximum peak concentrations (Cmax) as IR tablets of Ferriprox®, when the IR tablets were given three times a day, and the total amount absorbed (AUC) was the same for both products over a 24-hour period.
- Cmax maximum peak concentrations
- AUC total amount absorbed
- the invention also provides a process for the preparation of a coated deferiprone tablet as described above, which process comprises: i) mixing deferiprone with the modifying release agent and the pharmaceutically acceptable excipients, if present, to form a mixture; ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce a granulate; iii) mixing the granulate obtained in step (ii) with the lubricant and/or glidant excipient to form a mixture; iv) compressing the mixture obtained in step (iii) to form a tablet; v) and coating the tablet.
- the process comprises the following steps: i) mixing deferiprone with the modifying release agent and the pharmaceutically acceptable excipients, if present, to form a mixture; ii) adding the lubricant and/or glidant excipient and further mixing; iii) directly compressing the mixture obtained in step (ii) to form a tablet; and iv) coating the tablet.
- the tablets could be prepared in any suitable weight, but preferably the weight of each single unit would be in the range of 800 to 1500 mg, preferably of 1000 mg to 1200 mg.
- the present invention provides dosing regimens useful for the therapeutic use of the pharmaceutical formulations described herein.
- the oral daily dose of deferiprone could range from 75 mg/kg to 100 mg/kg.
- the deferiprone composition of the present invention is administered to a subject in need thereof twice daily.
- the unit dose of deferiprone the tablets shall be comprised between 500 and 1200 mg, preferably between 600 and 1000 mg, depending on the frequency of administration.
- the claimed formulations are useful for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron
- the subject in need thereof suffers from iron overload due to transfusional iron overload, or due diseases such as thalassemia, myelodysplasia, sickle cell disease or hemochromatosis.
- the subject in need thereof suffers from a neurodegenerative disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's Ataxia, Pantothenate Kinase Associated Neurodegeneration (PKAN), or neurodegeneration with brain iron accumulation (NBIA).
- a neurodegenerative disease e.g., Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's Ataxia, Pantothenate Kinase Associated Neurodegeneration (PKAN), or neurodegeneration with brain iron accumulation (NBIA).
- the subject in need thereof suffers from iron overload that is transfusional iron overload. In certain aspects, the subject suffers from transfusional iron overload and whose prior chelation therapy is inadequate.
- the subject suffers from transfusion iron overload and has a cardiac MRI T2* of 20 ms or less (e.g., 10 ms).
- Tablets were prepared by direct compression using a rotary tablet press (Officine Meccaniche Ronchi, AM8S) equipped with oblong punches having dimensions of 22 mm X 10 mm. Compression force was set at 25 kN in order to have tablets with a crushing strength of about 70 N.
- a rotary tablet press (Officine Meccaniche Ronchi, AM8S) equipped with oblong punches having dimensions of 22 mm X 10 mm. Compression force was set at 25 kN in order to have tablets with a crushing strength of about 70 N.
- hydrophilic matrices consisted of mixtures containing 1000 mg of active and different percentages of hypromellose polymer (HPMC) in two viscosity grades (Methocel® K100LV, Methocel® K4M, Colorcon, USA).
- compositions of dissolution media are reported below. pH 1.2: for 1 L, 3.73 g KC1, 7.07 ml HC1 1 N (deionized water up to volume); pH 4.5: for 1 L, 6.80 g of KH2PO4 (deionized water up to volume); pH 6.8: for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH ⁇ deionized water up to volume).
- the release test of the commercial product was analyzed at the wavelength of 276 nm both in pH 4.5 phosphate, and with the pH change mode (HCI 0.1 N for the first 120 minutes and phosphate buffer pH 6.8 for the remainder of the test). At high values of absorbance (over 30% of the release) sampling, dilutions and manual readings was performed.
- the active ingredient was quantified by spectrophotometry at a wavelength of 243 nm.
- the tablets comprising Methocel® K100LV 7,5% or a mixture of Methocel® K100LV 2% and K4M 3% exhibit the release profile more similar to the reference product.
- Methocel® K100LV 2% and K4M 3% were selected to be coated with a gastroresistant film.
- Eudragit® L30-D55 aqueous dispersion 60% w/w (containing 25% solids)
- Coating process lasted for 20 minutes and samples were collected every 5 minutes in order to test different coating amounts by dissolution test. The analysis has been carried out in the same conditions of the previous ones.
- K100LV 7.5% tablets had more difficulties in getting coated in the first minutes.
- the coating process lasted 5 minutes more than for the K100LV 2% K4M 3% tablets; both reached a 2% weight at the end.
- Eudragit® L100 dissolution pH around 6.8 in an alcoholic solution (10% w/w) with triethyl citrate (3% w/w in relation with the polymer) was applied.
- the coating process has been conducted in a small coating pan (opening diameter 10cm) and with the following process parameters:
- the process has been stopped when the tablets reached a weight gain (wg) of 3%.
- Dissolution tests have been conducted at 37 ° in Apparatus 1 (basket) with a rotational speed of 100 rpm in the following dissolution media: pH 1.2 (for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume) for the first 120 minutes pH 6.8 (for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume) for the rest of the dissolution time.
- pH 1.2 for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume
- pH 6.8 for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume
- the release profile of the half tablets according to the invention, coated with Eudragit® L30- D55 was also investigated versus half tablets of the reference product.
- Dissolution tests have been conducted at 37 0 in Apparatus 1 (basket) with a rotational speed of 100 rpm in the following dissolution media: pH 1.2 (for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume) for the first 120 minutes pH 6.8 (for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume) for the rest of the dissolution time.
- pH 1.2 for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume
- pH 6.8 for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume
- the half tablets of the invention when a change of the pH occurs, do not show any undesired burst effect, with a smoother release of the active ingredient in the first phase of the dissolution.
Abstract
The invention is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit delayed release properties when administered as either whole or half tablets. In particular, the invention is directed to delayed release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The invention is also directed to methods of making and using the same.
Description
MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING
DEFERIPRONE
FIELD OF INVENTION
The invention relates to pharmaceutical formulations comprising the iron chelator deferiprone.
In particular the invention is directed to a modified release formulation suitable for twice-a- day oral administration for the treatment of iron overload which occurs in patients suffering for example, from thalassemia, sickle cell disease, hemochromatosis, and myelodysplasia.
BACKGROUND OF THE INVENTION
Deferiprone, also known as 3-hydroxy- l,2-dimethylpyridin-4-one, is a bidentate ligand which binds to iron in a 3 : 1 molar ratio.
It is used in the treatment of generalized iron overload, particularly in conditions where frequent blood transfusions lead to iron overload including, e.g., thalassemia and Sickle Cell Disease (SCD).
The introduction of deferiprone in the current therapy has represented an important advancement as it Liver Iron Concentration (LIC) and cardiac iron overload.
In particular, Maggio A et al. Blood Cells Mol Dis. 2002, 28(2): 196-198) and Galanello R et al. Haematologica. 2006, 91(9): 1241-1243 suggested that deferiprone monotherapy seems to be superior to deferoxamine monotherapy in improving myocardial siderosis and cardiac function.
With regards to safety, the most frequent adverse events are gastrointestinal disorders due to gastrointestinal irritation. Such discomfort could cause patients to refrain from taking the medication, leading to a worsening of their condition. Other observed adverse events are musculoskeletal disorders (arthralgia), Alanine Aminotransferase (ALT) increase, agranulocytosis and neutropenia.
Agranulocytosis seems to be an idiosyncratic response and it is more frequent in the first year of treatment. The incidence of neutropenia and agranulocytosis is stable and seems to be not related with dose (Hider RC et al N Engl J Med. 2018;379:2140-2150).
Deferiprone is endowed with a long half-life of 2-3 hour) but with an unpleasant bitter taste.
Said drug is sold as Immediate Release (IR) 500 mg and 1000 mg tablets, as well as a 100 mg/ml liquid formulation, generally, under the trade name Ferriprox®.
In view of its pharmacological and ADME profile, and in order to improve the compliances of the patients, recently, deferiprone has also been launched commercially as 1000 mg Delayed Release (DR) tablets for oral administration.
Said tablets are suitable for a twice daily administration being bioequivalent in the steady state to the same daily dose of an immediate release tablet administered three times daily.
The commercial tablets are also debossed with a score line, to make it easy for the patient to break the tablets into two approximately equal parts for dosing flexibility.
The composition of the DR tablets has been disclosed in WO 2019/082128, and it comprises: (a) a core comprising the active pharmaceutical ingredient and an enteric polymer with pH- dependent solubility, and (b) an enteric coating.
In fact, the oral pharmaceutical dosage forms containing deferiprone, due to its potential for irritation and damage to the gastric mucosa and the relatively high solubility in an acid environment, shall be provided with an enteric coating (e.g. polymeric films with solubility at pH> 5 ) in order to avoid, or at least reduce, the release of the active principle during the permanence of the unit in the stomach, avoiding reaching plasma concentrations responsible for possible systemic adverse reactions.
To sustain the release, in the case of the marketed deferiprone product, as enteric polymer in the tablet core, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) is used.
However, HPMC-AS has a pH-dependent solubility.
This could lead to a release influenced by the external environment that the unit has to face during the transit along the regions in which the release of the active principle takes place, that are characterized by physiological fluids having different pH's, and hence less predictable being at the mercy of random microenvironmental variation of the pH.
Therefore, it would be advantageous to provide a tablet suitable for twice a day oral administration, with improved properties in terms of reproducibility of the expected release profiles.
Some documents of the prior art disclose deferiprone formulations comprising inter alia hydroxypropylmethyl cellulose polymer as excipient (Aguilar-De-Levya A et al Pharm Dev Tech 2014, 19,728-734; Kaul D et al J Drug Dev Ind Pharm 1992, 18, 1023-1035; US 2006/122273; CN 106983746). However, they are silent about the problem of improving the reproducibility of the release profile.
The technical solution is provided by the present invention.
SUMMARY OF THE INVENTION
The invention provides a pharmaceutical formulation in form of modified release enteric coated tablets suitable for twice-a-day oral administration, wherein the core of the tablet comprises: a) deferiprone in an amount comprised between 85.0 to 95.0%, b) a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof
with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP as a modifying release agent in an amount comprised between 4.0 and 10.0%, c) a lubricant and/or glidant in an amount from 0.2 to 2.0%, and d) other suitable pharmaceutically acceptable excipients in an amount comprised between from 0 to 5%, all the amounts calculated by weight on the total weight of the formulation.
Other suitable pharmaceutically acceptable excipients may belong to the classes of pH adjusting agents, and bulking agents.
Therefore, in a second aspect the invention provides a process for the preparation of a coated deferiprone tablet as described above, which process comprises the following steps:
(i) mixing deferiprone with the modifying release agent and the other pharmaceutically acceptable excipients, if present, to form a mixture;
(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce a granulate;
(iii) mixing the granulate obtained in step (ii) with the lubricant and/or glidant excipient to form a mixture;
(iv) compressing the mixture obtained in step (iii) to form a tablet; and
(v) coating the tablet.
In an alternative aspect, the process comprises the steps of:
(i) mixing deferiprone with the modifying release agent and the other pharmaceutically acceptable excipients, if present, to form a mixture;
(ii) adding the lubricant and/or glidant excipient and further mixing;
(iii) directly compressing the mixture obtained in step (ii) to form a tablet; and
(iv) coating the tablet.
In a third aspect, the invention is directed to the claimed pharmaceutical composition for use for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron.
In a fourth aspect, the invention is directed to the claimed pharmaceutical composition in the manufacture of a medicament for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron.
In a fifth aspect, the invention refers to a method for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron thereof in a patient in a need thereof, said method comprising orally administering the claimed pharmaceutical composition.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 - Dissolution tests of HPMC formulations carried out in 900 ml of pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm. The line with a triangular indicator is referred to as the commercial product.
Figure 2- Dissolution tests of HPMC formulations carried out in 900 ml of pH 4.5 medium, paddle (apparatus 2) having rotational speed of 50 rpm. The line with a triangular indicator is referred to as the commercial product.
Figure 3 -Dissolution tests of HPMC formulations carried out in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm. The line with a triangular indicator is referred to as the commercial product
Figure 4 - Dissolution tests of HPMC formulations carried out in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm. The line with a triangular indicator is referred to as the commercial product
Figure 5- Dissolution tests of HPMC formulations carried out in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm. The line with a triangular indicator is referred to as the commercial product
Figure 6 - Dissolution tests of the half-coated tablets in 900 ml of pH 1.2 medium (120 min) and then pH 6.8 medium, basket (apparatus 1) having rotational speed of 100 rpm. The line with a triangular indicator is referred to as the commercial product
DEFINITIONS
As used herein, the indefinite articles "a" or "an" should be understood to refer to "one or more" of any recited or enumerated component. For example, "a tablet" refers to one or more tablets.
Also as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").
When the term "about" is used in conjunction with a numerical value or range, it modifies that value or range by extending the boundaries above and below the numerical values set forth. The term "about" is used herein to modify a numerical value above and below the stated value by a variance of 10 percent, up or down (higher or lower), i.e., ± 10%, unless a different variance is indicated (e.g., ± 30%, ± 20%, ± 5%, ± 1%, etc.).
Wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of and/or "consisting essentially of are also provided. To the extent that the term "includes" or "including" is used in the specification or the claims, it is
intended to be inclusive in a manner similar to the term "comprising" as that term is interpreted when employed as a transitional word in a claim.
As used herein, the term "active ingredient" or "active pharmaceutical ingredient" (API) or “drug” are used as synonymous and mean any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals.
The terms "iron overload" or "overload of iron" are used interchangeably herein and refer to medical conditions where the body contains or stores too much (or "excess") iron. An example is transfusional iron overload, where the excess iron is introduced by one or more blood transfusions.
In the present context, the term "hydrophilic" describes that something 'likes water', i.e. a hydrophilic molecule or portion of a molecule is one that typically is electrically polarized and capable of forming hydrogen bonds with water molecules, enabling it dissolve more readily in water than in oil or other "non-polar" solvents.
Conversely, the term "hydrophobic" denotes a compound tending to be electrically neutral and non-polar, and thus preferring other neutral and nonpolar solvents or molecular environments.
For “pH dependent solubility” it is meant a substance having different solubilities at different pHs. These pH-dependent solubility differences lead to pH-dependent dissolution profiles.
The expression “insoluble or poorly water soluble” refers to a substance having a solubility in water as defined in the European Pharmacopoeia Ed. 4th, 2003, page 2891.
"Core" or "tablet core" as used herein comprises an active ingredient, e.g., deferiprone, and one or more excipients compressed into an uncoated tablet. The core can be coated with various coatings, including an enteric coating.
In the present context, the terms "controlled release", “prolonged release”, "modified release" and “delayed release” are intended to be equivalent terms covering any type of release of deferiprone from a composition of the invention that is appropriate to obtain a specific therapeutic or prophylactic response after administration to a subject". The terms refer to protecting an active ingredient, e.g., deferiprone, from rapid release at acidic pH, e.g., in the stomach, while enabling the active ingredient to be released at a higher rate at a higher pH, e.g., in the intestines. In some aspects, DR will be understood to mean that, when tested in USP apparatus 2 at 75 rpm, the extent of dissolution will be around 20 ± 5% at 1 hour in 0.1N HC1, and the rate of dissolution will be substantially higher (e.g., over 30%, e.g. over 40%, in 1 hour) in phosphate buffer with pH 6.8 than the rate of dissolution in 0. IN HC1.
"Disintegrant" as used herein refers to an excipient that is insoluble in water, but swells when wetted to cause a tablet to disintegrate.
"Dissolution" as used herein refers to the process by which a solute forms a solution in a solvent.
"Enteric coat" or "enteric coating" as used herein refers to a coating comprising an enteric polymer. An enteric coating can serve to prevent or delay a tablet's dissolution or disintegration in a gastric environment.
For “burst effect” it is meant the initial rapid release before the release rate reaches a stable profile, occurring immediately upon at the change of pH in the release medium.
"Enteric coated tablet" means a tablet having a core comprising an active ingredient, which is coated with an enteric coating.
"Enteric polymer" as used herein is understood to mean a polymer that is relatively insoluble at the acidic pH of the fasted stomach (e.g., about pH 1 to about pH 4), but soluble at higher pH (e.g., about pH 4.5 to about pH 8), which corresponds to the pH in the small intestine or thereafter, particularly in the duodenum or ileum.
The terms “fillers”, “diluents” and “bulking agents” are used as synonymous.
With the term “bioequivalence" it is meant the absence of a significant difference between the bioavailability, i.e., the extent of absorption and peak concentration, between two pharmaceutical drug products (e.g., a test product and a reference product) over the course of a period of time, at the same dose and under the same conditions,
The determination of whether or not a test product is bioequivalent to a reference product is determined by performing a study, referred to as a bioequivalence or comparative bioavailability study, in a group of subjects, usually about 18-36 subjects or more, under controlled conditions.
The study can be done in a "crossover" design, which means that the study is done in 2 or more phases, usually at least a week apart, depending in part on the half-life of the drug. In the first phase, half the subjects are randomly assigned to ingest the test product first and the other half ingest the reference product first. In the second phase, each subject ingests the alternate product.
In each phase, blood samples are drawn from each subject, on a predetermined schedule after ingestion of the test product. The blood samples are then analyzed to determine serum concentrations of the drug (test product, e.g., deferiprone) at each time point. For example, drugs are bioequivalent if they enter circulation at the same rate when given in similar doses under similar conditions. Parameters often used in bioequivalence studies are tmax, Cmax, Cmin, AUCo- inf ini ty , AUC 0-t .
In the present context "tmax" denotes the time to reach the maximal plasma concentration (Cmax) after administration; AUCo-infmity denotes the area under the plasma concentration versus time curve from time 0 to infinity; AUCo-t denotes the area under the plasma concentration versus time curve from time 0 to time t; W50 denotes the time where the plasma concentration is 50% or
more of CmaX; W75 denotes the time where the plasma concentration is 75% or more of CmaX; and MRT denotes mean residence time for tacrolimus.
"Fasted state" as used herein refers to abstinence from food for a defined period of time after a meal (typically, at least several hours, e.g., 4 or 6 hours, after a meal).
“Fed state" as used herein refers to administration with a meal or soon after a meal (e.g., within about 1 hour).
The term “chemical stable” refers to stability of the active agent in the formulation, wherein changes in the drug assay values and/or impurities content are equal to or lesser than 5%, preferably lesser than 3%, during storage at 25°C and 60% relative humidity (RH), or 40°C and 75% RH, for at least 1 month.
The term “vitro-in vivo correlation (IVIVC) refers an in vitro dissolution test that is predictive of the in vivo performance of the drug product.
"Gastric distress" as used herein refers to discomfort of the gastrointestinal (GI) tract, e.g., one or more of pain, cramping, bloating, nausea, indigestion, heartburn, and gas.
"Half tablet" as used herein means either of the two parts of a tablet obtained by splitting the tablet into two parts of equal or approximately equal weight. In some embodiments, a half tablet is from about 40% to about 60% by weight of the whole tablet from which the half was derived. In some aspects, the approximately equal weight of each half tablet is about 45-55% of the total weight of the whole tablet.
"Percent" or "%" as used herein refers to weight percentage (w/w) unless otherwise specified.
"Scored tablet" as used herein refers to a tablet that is debossed with one or more lines, also known as a "score line", to facilitate splitting the tablet, e.g., to enable administration of a half tablet. In some aspects, the tablet can be scored with two, three, four, or more score lines.
"Tablet" as used herein refers a solid oral pharmaceutical dosage form. In some embodiments, the tablet is a compressed tablet.
"Whole tablet" means a complete tablet, i.e., not broken or split into parts.
In the present context, viscosity is expressed in centipoise (1 cP = 0.01 P) which is more commonly used than the poise itself. The analogous unit in the International System of Units is the pascal-second (Pa-s). 1 cP corresponds to 1 mPa s.
Terms such as "treating" or "treatment" or "to treat" or "ameliorating" or "alleviating" or "to alleviate" can refer to both 1) therapeutic measures that cure, slow down, lessen symptoms of, reverse, and/or halt progression of a diagnosed pathologic condition or disorder and 2) prophylactic or preventative measures that prevent, reduce the incidence of, reduce the risk of, and/or slow the development of a targeted pathologic condition or disorder. Thus, those in need of
treatment include those who already have the disorder; those prone to developing the disorder; and those in whom the disorder is to be prevented. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those who already have the condition or disorder as well as those prone to developing the condition or disorder or those in which the condition or disorder is to be prevented or incidence reduced.
By "subject" or "individual" or "patient," is meant any human subject, for whom diagnosis, prognosis, treatment, or therapy is desired.
By "therapeutically effective dose or amount" or "effective amount" is intended an amount of active pharmaceutical ingredient, e.g., deferiprone, that when administered brings about a positive therapeutic response with respect to treatment of or reducing the risk of a disease in a subject to be treated.
It will be understood that the deferiprone DR tablets used as the "reference" or "reference product" herein are Ferriprox® tablets (1000 mg) as approved by FDA and sold in the United States.
DETAILED DESCRIPTION OF THE INVENTION
The present invention concerns pharmaceutical formulations for the prevention and/or treatment of diseases which are caused by an excess of iron, especially compositions providing modified release of the active ingredient.
The active ingredient in the inventive formulations is deferiprone. However, within the scope of the present invention is deferiprone in any physical form (crystals, amorphous powder, any possible polymorphs, any possible solvate. Included are also pharmaceutically acceptable salts and/or solvates thereof. Preferably, deferiprone is used as a base in its anhydrous form.
According to a first embodiment, the invention is directed to a pharmaceutical formulation in form of modified release enteric coated tablets suitable for twice-a-day oral administration, wherein the core of the tablet comprises; a) deferiprone in an amount comprised between 85.0 to 95.0%, b) a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP as a modifying release agent in an amount comprised between 4.0 and 10.0%, c) a lubricant and/or glidant in an amount from 0.2 to 2.0% and d) other suitable pharmaceutically acceptable excipients in an
amount comprised between from 0 to 5%, all the amounts calculated by weight on the total weight of the formulation.
It has been found that, within the limits of the statistical significance, an in vitro release similar to commercial deferiprone DR tablets could be obtained with hydrophilic polymers as modifying release agent.
In particular, the tablet-core of the pharmaceutical dosage form object of the present invention has the advantage of having a composition based on excipients with non-pH-dependent solubility, and hence they are not directly interfering with the release of deferiprone at the different pH values of the gastrointestinal tract.
This substantiates an undeniable improvement in terms of reproducibility of the expected release profiles.
A further surprising advantage linked to the use of these polymers will become evident from the following description.
Advantageously hydroxyproylmethylcellulose polymer (HPMC) Methocel® K100LV which is a thickener with low substitution, yielding a viscosity of about 100 cP at a 2% addition in water at 20°C.
Said polymer could be used in combination with hydroxyproylmethylcellulose polymer (HPMC) Methocel®K4M which is a medium molecular weight hydroxypropyl methylcellulose (HPMC) thickener. It will yield a viscosity of about 4,000 cP at a 2% addition in water at 20°C.
They are both commercially available from DuPont (Delaware, USA) or from Colorcon Inc (California, USA).
Advantageously, is modifying release agent in present in an amount comprised between 4.0 and 10.0%, preferably between 7 and 8% by weight.
In a preferred embodiment, Methocel® K100LV could be used alone in an amount of 7.5%, while in another preferred embodiment, a mixture of Methocel® K100LV and Methocel® K4M in an amount of 5% by weight could be utilised, preferably wherein the two polymers are in the amount of 2% and 3.0% by weight, respectively (ratio 40:60 w/w).
Deferiprone may cause gastric irritation if released in the fasted stomach, and some degradation by acidic hydrolysis.
Therefore, the tablets of the invention will be provided by an enteric coating, which serves both to delay dissolution of deferiprone and to avoid dissolution in the stomach, in particular in fasted patient, and a diluent such as water, ethanol, propylene glycol or mixture thereof.
Due to the coating, the tablets as per the invention are formulated to have a neglectable dissolution in the fasted stomach but will more rapidly dissolve in the intestines.
Suitable enteric polymers for the enteric coating include, e.g., hydroxyxypropyl methylcellulose acetate succinate (also referred to as hypromellose acetate succinate or HPMCAS), HPMC phthalate (also referred to as hypromellose phthalate), polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, shellac, zein, methacrylic acid copolymers (e.g., methacrylic acid copolymer Type C Dispersion 30%), derivatives thereof, and any combination thereof.
In some embodiments, the preferred enteric polymers in the enteric coating are HPMC acetate succinate and methacrylic acid copolymers, e.g., methacrylic acid copolymer type C, in aqueous dispersion.
In some embodiments, the enteric polymer in the coating is about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.5%, 3%, 3.5%, or 4%, by weight of the tablet, or a range between any two of the preceding values, e.g., 0.5-1%, 0.5-2%, 0.5-3%, 0.5-4%, 0.6-1%, 0.6-2%, 0.6-3%, 0.6-4%, 0.7-1%, 0.7-2%, 0.7-3%, 0.7-4%, 1-1.5%, 1.1- 1.7%, 1-2%, 1.5-2%, 1-3%, 1-3.5%, or 1-4%, by weight of the tablet. In other embodiments, the enteric polymer in the coating is about 2.0% or about 3.0% by weight of the tablet.
It has been found that, for the tablets of the present invention, a thicker coating (2-3% by weight) would be preferable to obtain a release profile similar to the reference product, whose coating is about 1-4-1.5% weight.
In some embodiments, the enteric coating comprises, in addition to the enteric polymer, other excipients, including for example, a plasticizer, a lubricant or anti-tack agent such as talc, an opacifier, a colorant, a diluent, or any combination thereof.
Advantageously, the enteric coating plasticizer is diethyl phthalate, citrate esters such as triethyl citrate, polyethylene glycol, glycerol, acetylated glycerides, acetylated citrate esters, dibutyl sebecate, castor oil, or any combination thereof.
In other embodiments, the enteric coating may further comprise a diluent e.g., lactose, sucrose, fructose, mannitol, and the like, or combinations thereof. In some embodiments, the enteric coating comprises talc as the lubricant or anti-tack agent.
In a preferred embodiment the enteric coating comprises a methacrylic acid copolymer dispersion, preferably an ethacrylic acid - ethyl acrylate copolymer (1 :1) dispersion in water and propylene glycol. The ethacrylic acid - ethyl acrylate copolymer (1 : 1) is known as Eudragit® L30- D55 and is commercially available from Evonik Operations GmbH, Essen Germany.
In an alternative preferred embodiment, the enteric coating comprises methacrylic acid- methacrylate copolymer (1 : 1) in an alcoholic solution, preferably in concentration of 5-15% w/w, more preferably 10% w/w, with tri ethyl citrate as plasticizer, preferably in a concentration in relation to the polymer of 2-5% w/w, more preferably of 3% w/w.
Methacrylic acid- methacrylate copolymer (1 :1) is known as Eudragit® L100 (dissolution pH around 6.8) and is commercially available, for example from Sigma-Aldrich (Missouri, USA).
The coating shall be performed according to methods known to the skilled person, typically for a time comprised 15 and 20 minutes.
In some embodiments, the core may comprise one or more pharmaceutically acceptable excipients such as bulking agents and/or basic excipient.
Advantageously, the buking agent that when present is utilizes to increase tablet hardness, could be selected from the group consisting of calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrans, dextrin, dextrose, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, alpha-lactose monohydrate.
Advantageously the basic excipient could be selected from the group consisting of metal oxides, metal hydroxides, basic salts of weak acids, and a combination thereof. Metal oxides include, but are not limited to, magnesium oxide, aluminum oxide, and zinc oxide. Metal hydroxides include, but are not limited to, sodium hydroxide, potassium hydroxide, magnesium hydroxide, and calcium hydroxide. Basic salts of weak acids include, but are not limited to, sodium or potassium salts of carbonate, bicarbonate, acetate, and citrate. In certain embodiments, the basic excipient is magnesium oxide, meglumine or a combination thereof. In some embodiments, the basic excipient is magnesium oxide.
The tablets shall also comprise a lubricant to prevent sticking to the tooling during compression into tablets), and/or a glidant to improve flow in the tableting process), or combinations thereof.
Advantageously, the lubricant is selected from the group consisting of, but not limited to, magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, or combination thereof.
Preferably the lubricant is magnesium stearate.
Advantageously, the glidant is selected from the group consisting of, but not limited to, colloidal silicon dioxide, starch and talc, preferably colloidal silicon dioxide or any combination thereof.
In a preferred embodiment, the core of tablet comprises a mixture of magnesium stearate and colloidal silicon dioxide.
As an exemplary embodiment, the core of said coated formulations comprises: a) deferiprone in an amount of 91% by weight; b) Methocel® K100LV in an amount of 7.5% by weight; and c) a mixture of a lubricant and glidant in an amount of 1.5% by weight.
In another exemplary embodiment, the core of the coated formulation comprises: a) deferiprone in an amount of 93% by weight: b) Methocel® K100LV in an amount of 2.0% by weight; c) Methocel ®K4M in an amount of 3.0 by weight; d) a mixture of a lubricant and glidant in an amount of 2.0% by weight.
Advantageously, the pharmaceutical tablets of the invention are debossed with a score line, to make it easy for the patient to break the tablets into two approximately equal parts to enable administration of half tablets, allowing a dosing flexibility.
Needless-to-say, when the tablet is broken, its surface at the interface is no longer protected by the enteric coating, and some dissolution in the stomach acid could be observed.
On the other hand, as long as said dissolution is around 20% % at acidic pH, or even better below this value, this is considered acceptable.
As a further advantage, as reported in Figure 6, although the release is a little bit higher at low pH than the commercial tablets was observed, the half tablets of the invention, when a change of the pH occurs, do not show any undesired burst effect, and exhibit a smoother release of the active ingredient in the first phase of the dissolution.
In fact, it is well known that transient higher concentrations and hence plasma levels of deferiprone, could be associated with transient increase of liver enzymes and other side effects (Cohen ER et al Br J Haematology, 2000, 108, 305-312).
Advantageously, a tablet of the present disclosure embraces the attributes of an enteric coated tablet without its deficiencies, so that tablets can be halved, to enable fine tuning of the dosing to administer whole tablets, half tablets or any combination thereof. Half tablets of the disclosure substantially resist dissolution in acidic media (0.1 N HC1), representing the fasted stomach contents, as do whole tablets; and, at a higher pH, representing the contents of the small intestine, also exhibit a rate of dissolution similar to whole tablets, but without the undesired burst effect of the reference product on the market.
The release profile of the tablets of the invention has been determined in different dissolution media varying the pH according to the conditions reported in Examples 2 and 3.
Since it has been reported in WO 2019/082128for Ferriprox® tablets, that deferiprone modified release formulations exhibit a good IVIV correlation -, it is contemplated that the in vitro release profile will reflect the in vivo behaviour.
The tablets according to the invention give rise to a dissolution profile at pH 6.8 similar to that of Ferriprox® tablets as approved by FDA and sold in the United States, so it is contemplated
that they will show the same bioavailability at the steady state, making it suitable for a twice a day oral administration.
It is contemplated that said formulation would turn out to be bioequivalent in the steady state, to the immediate release Ferriprox® tablets for three times a day administration, the mean ratio of AUC (over 24 hours) and the mean ratio of Cmax for the tablets of the invention relative to the immediate release (IR) tablets would be within 80% to 125%.
In other words, in the steady state, the modified release tablets of the present invention when administered twice-a-day would be able to achieve the same maximum peak concentrations (Cmax) as IR tablets of Ferriprox®, when the IR tablets were given three times a day, and the total amount absorbed (AUC) was the same for both products over a 24-hour period.
The invention also provides a process for the preparation of a coated deferiprone tablet as described above, which process comprises: i) mixing deferiprone with the modifying release agent and the pharmaceutically acceptable excipients, if present, to form a mixture; ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce a granulate; iii) mixing the granulate obtained in step (ii) with the lubricant and/or glidant excipient to form a mixture; iv) compressing the mixture obtained in step (iii) to form a tablet; v) and coating the tablet.
In an alternative embodiment, the process comprises the following steps: i) mixing deferiprone with the modifying release agent and the pharmaceutically acceptable excipients, if present, to form a mixture; ii) adding the lubricant and/or glidant excipient and further mixing; iii) directly compressing the mixture obtained in step (ii) to form a tablet; and iv) coating the tablet.
Apparatus and conditions for direct compression and/or compression upon granulation are known to the skilled person in the art.
The tablets could be prepared in any suitable weight, but preferably the weight of each single unit would be in the range of 800 to 1500 mg, preferably of 1000 mg to 1200 mg.
For avoidance of doubts, reference is made to the extensive literature on the subject for these and other pharmaceutically acceptable excipients and procedures mentioned herein, see in particular Handbook of Pharmaceutical Excipients, Third Edition, edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, USA and Pharmaceutical Press, London; and
Lexikon der Hilfsstoffe fi.ir Pharmazie, Kosmetik and angrenzende Gebiete edited by H.P. Fiedler, 4th Edition, Editor Cantar, Aulendorf and earlier editions.
.The present invention provides dosing regimens useful for the therapeutic use of the pharmaceutical formulations described herein.
Typically, the oral daily dose of deferiprone could range from 75 mg/kg to 100 mg/kg.
In some embodiments, the deferiprone composition of the present invention is administered to a subject in need thereof twice daily.
The unit dose of deferiprone the tablets shall be comprised between 500 and 1200 mg, preferably between 600 and 1000 mg, depending on the frequency of administration.
The claimed formulations are useful for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron
In some embodiments, the subject in need thereof suffers from iron overload due to transfusional iron overload, or due diseases such as thalassemia, myelodysplasia, sickle cell disease or hemochromatosis.
In some embodiments, the subject in need thereof suffers from a neurodegenerative disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Friedreich's Ataxia, Pantothenate Kinase Associated Neurodegeneration (PKAN), or neurodegeneration with brain iron accumulation (NBIA).
In some embodiments, the subject in need thereof suffers from iron overload that is transfusional iron overload. In certain aspects, the subject suffers from transfusional iron overload and whose prior chelation therapy is inadequate.
In certain aspects, the subject suffers from transfusion iron overload and has a cardiac MRI T2* of 20 ms or less (e.g., 10 ms).
The invention is illustrated in detail by the following examples.
EXAMPLES
Example 1 - Preparation of the tablets
Tablets were prepared by direct compression using a rotary tablet press (Officine Meccaniche Ronchi, AM8S) equipped with oblong punches having dimensions of 22 mm X 10 mm. Compression force was set at 25 kN in order to have tablets with a crushing strength of about 70 N.
The hydrophilic matrices consisted of mixtures containing 1000 mg of active and different percentages of hypromellose polymer (HPMC) in two viscosity grades (Methocel® K100LV, Methocel® K4M, Colorcon, USA).
Example 2 - Dissolution test
The spectrum of maximum absorption of the active was acquired in the various fluids in which the release tests will be conducted by means of a spectrophotometer.
Compositions of dissolution media are reported below. pH 1.2: for 1 L, 3.73 g KC1, 7.07 ml HC1 1 N (deionized water up to volume); pH 4.5: for 1 L, 6.80 g of KH2PO4 (deionized water up to volume); pH 6.8: for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH {deionized water up to volume).
Calibration curves were built for each of the release media both at the wavelength of 276 nm at which a peak of absorbance was recorded, and at 243nm, in which reduced absorption was observed, in order not to exceed the instrument maximum absorbance value.
The release test of the commercial product was analyzed at the wavelength of 276 nm both in pH 4.5 phosphate, and with the pH change mode (HCI 0.1 N for the first 120 minutes and phosphate buffer pH 6.8 for the remainder of the test). At high values of absorbance (over 30% of the release) sampling, dilutions and manual readings was performed.
Release tests were carried out in a dissolution test paddle apparatus (USP type 2) with a rotation speed of 50 rpm and basket apparatus (USP type 1) with a rotation speed of 100 rpm. The tests were always conducted in 900 mL of dissolution medium at 37 °C.
For the experimental formulations, the active ingredient was quantified by spectrophotometry at a wavelength of 243 nm.
The results for the uncoated tablets at pH 6.8 and 4.5 are reported in Figures 1 and 2.
It can be appreciated that, the tablets comprising Methocel® K100LV 7,5% or a mixture of Methocel® K100LV 2% and K4M 3% exhibit the release profile more similar to the reference product.
Example 3 - Gastroresistant coating
Starting from the results of the non-coated tablets, those formulated with
Methocel® K100LV 7.5%
Methocel® K100LV 2% and K4M 3% were selected to be coated with a gastroresistant film.
Tablets were then coated with a different acrylic polymer having a dissolution pH around 6 and formulated in aqueous dispersion:
Eudragit® L30-D55 aqueous dispersion 60% w/w (containing 25% solids)
Deionized water 38% w/w
Propylene glycol 2% w/w
Process parameters were the followings:
Nozzle: 0.8 mm
Atomization pressure: 0,8 bar
Control pressure: 2 bar
Pattern pressure: 0,5 bar
Peristaltic pump: 2 rpm
Air temperature: 57 °C
Coating process lasted for 20 minutes and samples were collected every 5 minutes in order to test different coating amounts by dissolution test. The analysis has been carried out in the same conditions of the previous ones.
The results are reported in Figures 3 and 4.
K100LV 7.5% tablets had more difficulties in getting coated in the first minutes. For this formulation, in fact, the coating process lasted 5 minutes more than for the K100LV 2% K4M 3% tablets; both reached a 2% weight at the end.
As an alternative method of coating, Eudragit® L100 (dissolution pH around 6.8) in an alcoholic solution (10% w/w) with triethyl citrate (3% w/w in relation with the polymer) was applied.
The coating process has been conducted in a small coating pan (opening diameter 10cm) and with the following process parameters:
Nozzle: 0.8 mm
Atomization pressure: 0,5 bar
Control pressure: 0,6 bar
Pattern pressure: 2 bar
Peristaltic pump: 2 rpm
Air temperature: 50 °C
The process has been stopped when the tablets reached a weight gain (wg) of 3%.
Dissolution tests have been conducted at 37 ° in Apparatus 1 (basket) with a rotational speed of 100 rpm in the following dissolution media: pH 1.2 (for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume) for the first 120 minutes pH 6.8 (for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume) for the rest of the dissolution time.
The results are reported in Figure 5.
It can be appreciated, that a release very similar to the reference product was obtained for the K100LV 7.5% tablets.
The release profile of the half tablets according to the invention, coated with Eudragit® L30- D55 was also investigated versus half tablets of the reference product.
Dissolution tests have been conducted at 37 0 in Apparatus 1 (basket) with a rotational speed of 100 rpm in the following dissolution media: pH 1.2 (for 1 L, 3.73 g KC1, 7.07 mL HC1 IN and deionized water up to volume) for the first 120 minutes pH 6.8 (for 1 L, 6.80 g KH2PO4, 0.90 g of NaOH and deionized water up to volume) for the rest of the dissolution time.
The results are reported in Figure 6.
As it can be observed from the Figure, although the release of the active ingredient is a little bit higher at low pH than the commercial tablets, the half tablets of the invention, when a change of the pH occurs, do not show any undesired burst effect, with a smoother release of the active ingredient in the first phase of the dissolution.
Claims
1 A pharmaceutical formulation in form of modified release enteric coated tablets suitable for twice-a-day oral administration, wherein the core of the tablet comprises: a) deferiprone in an amount comprised between 85.0 to 95.0%, b) a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP as a modifying release agent in an amount comprised between 4.0 and 10.0%, c) a lubricant and/or glidant in an amount from 0.2 to 2.0% and d) other suitable pharmaceutically acceptable excipients in an amount comprised between from 0 to 5%, all the amounts calculated by weight on the total weight of the formulation.
2 The pharmaceutical formulation according to claim 1, wherein the modifying release agent consists of a hydroxyproylmethylcellulose polymer having a viscosity of 100 cP in an amount of 7.5% by weight.
3 The pharmaceutical formulation according to claim 1, wherein the modifying release agent consists of a mixture of hydroxyproylmethylcellulose polymer having a viscosity of 100 cP alone or in mixture thereof with a hydroxyproylmethylcellulose polymer having a viscosity of 4000 cP in an amount of 5% by weight.
4 The pharmaceutical formulation according to claim 3, wherein the ratio between the two polymers is 40:60 w/w.
5 The pharmaceutical formulation according to any one of the preceding claims, wherein the lubricant is selected is selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, talc, and a combination thereof.
6 The pharmaceutical formulation according to claim 5, wherein the lubricant is magnesium stearate.
7 The pharmaceutical composition according to any one of the preceding claims, wherein the glidant is selected from the group consisting of colloidal silicon dioxide, starch and talc and combination thereof.
8 The pharmaceutical composition according to claim 7, wherein the glidant is colloidal silicon dioxide.
The pharmaceutical formulation according to any one of the preceding claims, wherein the other suitable pharmaceutically acceptable excipients are selected from the classes of pH adjusting agents, and bulking agents. The pharmaceutical formulation according to any one of the preceding claims, wherein the enteric coating comprises an enteric polymer, a diluent, and optionally a plasticizer. The pharmaceutical formulation according to claim 10, wherein the enteric coating comprises an ethacrylic acid - ethyl acrylate copolymer (1:1) dispersion in water and propylene glycol. The pharmaceutical formulation according to claim 10, wherein the enteric coating comprises methacrylic acid- methacrylate copolymer (1:1) in an alcoholic solution with tri ethyl citrate. The pharmaceutical formulation according to any one of the preceding claims, wherein the core of the tablet comprises from 500 to 1500 mg of deferiprone. The pharmaceutical formulation according to claim 13, wherein the core of the tablet comprises 1000 mg of deferiprone. The pharmaceutical formulation according to any one of the preceding claims, which is suitable for twice-day administration. A process for the preparation of the pharmaceutical formulation according to any one of claims 1 to 15, said process comprising the following steps:
(i) mixing deferiprone with the modifying release agent and the other pharmaceutically acceptable excipients, if present, to form a mixture;
(ii) wet-granulating the mixture obtained in step (i) in a high shear granulator followed by drying and screening to produce a granulate;
(iii) mixing the granulate obtained in step (ii) with the lubricant and/or glidant excipient to form a mixture; compressing the mixture obtained in step (iii) to form a tablet; and
(iv) coating the tablet. A process for the preparation of the pharmaceutical formulation according to any one of claims 1 to 15, said process comprising the following steps:
(i) mixing deferiprone with the modifying release agent and the other pharmaceutically acceptable excipients, if present, to form a mixture;
(ii) adding the lubricant and/or glidant excipient and further mixing;
(iii) directly compressing the mixture obtained in step (ii) to form a tablet; and (iv) coating the tablet. The pharmaceutical composition according to any one of claims 1 to 15, for use for the treatment of diseases which cause an overload of iron, or for the prevention and/or treatment of diseases which are caused by an overload of iron. The pharmaceutical composition for use according to claim 18, wherein the disease is thalassemia or sickle cell anemia. The pharmaceutical composition for us according to claim 18, wherein said iron overload is transfusional iron overload.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22167555 | 2022-04-11 | ||
EP22167555.6 | 2022-04-11 | ||
US17/717,922 | 2022-04-11 | ||
US17/717,922 US20230321061A1 (en) | 2022-04-11 | 2022-04-11 | Modified release pharmaceutical formulations comprising deferiprone |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023198640A1 true WO2023198640A1 (en) | 2023-10-19 |
Family
ID=86142894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/059303 WO2023198640A1 (en) | 2022-04-11 | 2023-04-07 | Modified release pharmaceutical formulations comprising deferiprone |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023198640A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122273A1 (en) | 2000-06-30 | 2006-06-08 | Apotex Inc. | Use for deferiprone |
CN106983746A (en) | 2017-03-23 | 2017-07-28 | 武汉联合药业有限责任公司 | A kind of medical composition and its use |
WO2019082128A1 (en) | 2017-10-25 | 2019-05-02 | Apotex Inc. | Delayed release deferiprone tablets and methods of using the same |
-
2023
- 2023-04-07 WO PCT/EP2023/059303 patent/WO2023198640A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060122273A1 (en) | 2000-06-30 | 2006-06-08 | Apotex Inc. | Use for deferiprone |
CN106983746A (en) | 2017-03-23 | 2017-07-28 | 武汉联合药业有限责任公司 | A kind of medical composition and its use |
WO2019082128A1 (en) | 2017-10-25 | 2019-05-02 | Apotex Inc. | Delayed release deferiprone tablets and methods of using the same |
Non-Patent Citations (10)
Title |
---|
"European Pharmacopoeia", 2003, pages: 2891 |
"Lexikon der Hilfsstoffe fi.ir Pharmazie, Kosmetik and angrenzende Gebiete", AMERICAN PHARMACEUTICAL ASSOCIATION |
AGUILAR-DE-LEVYA A ET AL., PHARM DEV TECH, vol. 19, 2014, pages 728 - 734 |
AGUILAR-DE-LEYVA ANGELA ET AL: "A new deferiprone controlled release system obtained by ultrasound-assisted compression", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, INFORMA HEALTHCARE, US, vol. 19, no. 6, 31 August 2014 (2014-08-31), pages 728 - 734, XP009518840, ISSN: 1097-9867, DOI: 10.3109/10837450.2013.829091 * |
COHEN ER ET AL., BR J HAEMATOLOGY, vol. 108, 2000, pages 305 - 312 |
GALANELLO R ET AL., HAEMATOLOGICA., vol. 91, no. 9, 2006, pages 1241 - 1243 |
HIDER RC ET AL., N ENGL J MED., vol. 379, 2018, pages 2140 - 2150 |
KAUL D ET AL., J DRUG DEV IND PHARM, vol. 18, 1992, pages 1023 - 1035 |
KAUL D ET AL: "Sustained release tablet formulation for a new iron chelator", JOURNAL DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 18, no. 9, 1 January 1992 (1992-01-01), pages 1023 - 1035, XP009539330, ISSN: 0363-9045 * |
MAGGIO A ET AL., BLOOD CELLS MOL DIS., vol. 28, no. 2, 2002, pages 196 - 198 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11173123B2 (en) | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix | |
AU2019268049B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
JP2012516299A (en) | Organic galenic formulation | |
EP2603207A2 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
AU2019268077B2 (en) | Pharmaceutical Composition Containing Acetaminophen | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
US20230321061A1 (en) | Modified release pharmaceutical formulations comprising deferiprone | |
WO2023198640A1 (en) | Modified release pharmaceutical formulations comprising deferiprone | |
US20230321060A1 (en) | Modified release pharmaceutical formulations comprising deferiprone | |
WO2023198641A1 (en) | Modified release pharmaceutical formulations comprising deferiprone | |
WO2005065662A1 (en) | Solid dosage formulations of galantamine | |
WO2024079303A1 (en) | Modified release pharmaceutical formulations comprising deferiprone | |
JP7195354B2 (en) | Pharmaceutical formulation containing one or more fumarates in an eroding matrix | |
US20210023073A1 (en) | Dextromethorphan extended release pharmaceutical composition | |
EP1713451A1 (en) | Solid dosage formulations of galanthamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23719009 Country of ref document: EP Kind code of ref document: A1 |